1. Home
  2. CUE vs VNRX Comparison

CUE vs VNRX Comparison

Compare CUE & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.27

Market Cap

27.8M

Sector

Health Care

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.19

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
VNRX
Founded
2014
N/A
Country
United States
United States
Employees
41
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8M
31.9M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
CUE
VNRX
Price
$0.27
$0.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.00
$2.50
AVG Volume (30 Days)
442.9K
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
35.14
38.00
EPS
N/A
N/A
Revenue
$9,287,000.00
$1,233,511.00
Revenue This Year
N/A
$68.22
Revenue Next Year
$25.00
$382.75
P/E Ratio
N/A
N/A
Revenue Growth
69.16
59.10
52 Week Low
$0.23
$0.17
52 Week High
$1.05
$0.94

Technical Indicators

Market Signals
Indicator
CUE
VNRX
Relative Strength Index (RSI) 39.65 36.92
Support Level $0.27 $0.17
Resistance Level $0.36 $0.27
Average True Range (ATR) 0.03 0.02
MACD 0.00 0.00
Stochastic Oscillator 14.60 17.93

Price Performance

Historical Comparison
CUE
VNRX

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Share on Social Networks: